Practical and Safe Method of Long-Term Cryopreservation for Clinical Application of Human Adipose-Derived Mesenchymal Stem Cells Without a Programmable Freezer Or Serum.
Gao S., Ogawa M., Takami A., Takeshita K., Kato H.
Laboratory Study, published in Cryo Letters (2020) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Cryo Letters (2020)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 33990810
- Citations
- 5
Abstract (original English)
Background Adipose-derived mesenchymal stem cells (ADSCs) have emerged as a promising modality for cellular therapy. However, techniques of ADSC cryopreservation, which can facilitate their clinical application, haven't been established yet. Objective To determine optimal conditions for ADSC cryopreservation. Materials and methods We used three cryoprotectants [serum containing 10% dimethyl sulfoxide; CP-1 TM (5% dimethyl sulfoxide, serum-free); Stem-CellBanker TM (dimethyl sulfoxide and serum-free)], two storage temperatures (-80°C, -150°C) and two cell densities (1 × 10 6 , 7 × 10 6 cells/mL). Storage was up to 18 months using cryovials. We didn't use a rate-controlled freezer or liquid nitrogen storage. Results We found that CP-1 TM was a suitable cryoprotectant. Storage at -150°C and higher cell density (7×10 6 cells/mL) kept the best viability of ADSCs, but storage at -80°C and a lower cell density (1×10 6 cells/mL) is acceptable for up to 9 months. We also confirmed large quantities of ADSCs, stored with CP-1 in a cryobag, were still viable after -150°C cryopreservation for 24 months. Conclusion We have developed a safe, cost-effective way to cryopreserve ADSCs that could be used in the clinical setting.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.